Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

12/23/2019 | 07:41pm EDT
FILE PHOTO: Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

The Swiss drugmaker closed a $4.3 billion deal to acquire Sparks Therapeutics this month, underscoring the growing appetite among large drugmakers for gene therapies.

Roche will make an upfront payment of $750 million in cash and take a $400 million stake in Sarepta, priced at $158.59 per share, a premium of about 26% to the U.S. drugmaker's closing price on Friday.

Shares of Sarepta, which already has non-gene therapies for DMD in the market, were up 9% at $138 before the bell.

"This deal should increase confidence in Sarepta's entire DMD gene therapy program, remove any financing overhang, and allow Sarepta to retain control and flexibility," Cantor Fitzgerald analyst Alethia Young said in a note.

Gene therapies, one of the hottest areas of drug research, aim to correct certain diseases by replacing the missing or mutated version of a gene found in a patient's cells with healthy copies.

Earlier this month, Japan's Astellas Pharma Inc said it was buying gene therapy developer Audentes Therapeutics Inc for about $3 billion - more than double the U.S. company's market value at the time.

DMD is a rare degenerative neuromuscular disorder, which affects about one in 3,500-5,000 male births worldwide, causes severe progressive muscle loss and premature death.

Sarepta already has a large presence in the DMD market. Its Exondys 51, a non-gene therapy that was approved in 2016, brought in sales of $99 million in the latest quarter. Earlier this month, the company gained a surprise U.S. approval for another DMD drug Vyondys 53.

The drugmaker is eligible to receive up to $1.7 billion in regulatory and sales milestones, plus royalties on net sales, Roche said, adding the agreement was expected to close in the first quarter of 2020.

Sarepta will continue to be responsible for the clinical development and manufacturing of the gene therapy, SRP-9001, while sharing global clinical development costs equally with Roche.

"This deal is as big as it gets for four patients worth of data and only ex-U.S. rights," Baird analyst Brian Skorney said in a note.

(Reporting by Silke Koltrowitz in Zurich and Dania Nadeem in Bengaluru; Editing by Tassilo Hummel, Subhranshu Sahu and Saumyadeb Chakrabarty)


© Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 0.35% 1889 End-of-day quote.18.51%
ROCHE HOLDING AG -0.65% 342.9 Delayed Quote.10.97%
SWISS RE LTD -1.75% 80.62 Delayed Quote.-3.26%
Latest news "Economy & Forex"
03:08aJapan's PM contender Kishida says won't raise sales tax for a decade
RE
03:07aChinese version of TikTok limits use of app by those under 14
RE
02:00aNigeria's central bank keeps rates steady, targets illegal FX dealers
RE
01:58aS&P revises Botswana's outlook to 'stable' on strong diamond sector recovery
RE
12:26aEvergrande says six execs redeemed investment products in advance
RE
12:22aMINISTRY OF EXTERNAL AFFAIRS OF REPUBLIC OF IN : Third Round of Foreign Office Consultations between India and El Salvador
PU
09/17PRESIDENT OF REPUBLIC OF TAJIKISTAN : Reception on behalf of the President of Tajikistan in honour of the CSTO and SCO leaders
PU
09/17China c.bank says sets 14-day reverse repo rate at 2.35% vs 2.35% previously
RE
09/17China c.bank says sets 7-day reverse repo rate at 2.20% vs 2.20% previously
RE
09/17U.S. resumes talks with Huawei CFO on resolving criminal charges - Globe and Mail
RE
Latest news "Economy & Forex"